Publications | PubMed=2854303; DOI=10.1620/tjem.156.319 Nozawa Y., Abe M., Wakasa H., Ohno H., Fukuhara S., Kinoshita T., Osato T. Establishment and characterization of an Epstein-Barr virus negative B-cell lymphoma cell line and successful heterotransplantation. Tohoku J. Exp. Med. 156:319-330(1988) PubMed=3338018; DOI=10.1002/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L Abe M., Nozawa Y., Wakasa H., Ohno H., Fukuhara S. Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability. Cancer 61:483-490(1988) PubMed=8558920 Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 10:142-149(1996) DOI=10.1016/B978-0-12-221970-2.50457-5 Drexler H.G. The leukemia-lymphoma cell line factsbook. (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001) PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x Kamimura K., Hojo H., Abe M. Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis. Pathol. Int. 54:224-230(2004) PubMed=20054396; DOI=10.1038/nature08638 Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88-92(2010) PubMed=21179087; DOI=10.1038/nature09671 Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. III, Romesser P., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M. Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115-119(2011) PubMed=23257783; DOI=10.1038/leu.2012.367 Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 27:1381-1390(2013) PubMed=26787899; DOI=10.1073/pnas.1524677113 Dekker J.D., Park D., Shaffer A.L. III, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016) PubMed=29416618; DOI=10.18632/oncotarget.20378 Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9:346-360(2018) PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004 Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin. Cancer Res. 24:3967-3980(2018) PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020 Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega-Vazquez F. Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Lett. 436:149-158(2018) PubMed=31510952; DOI=10.1186/s12885-019-6129-8 Takashima Y., Yoshimura T., Kano Y., Hayano A., Hondoh H., Ikenaka K., Yamanaka R. Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. BMC Cancer 19:910.1-910.11(2019) |